Icon
+91 94997 68112
Login Register

CRENESSITY - (25MG, 50MG, 100MG)

CRINECERFONT None
25MG, 50MG, 100MG
Less Than $1000 mn
None None
None None
None None
CRENESSITY is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
Yes
CRENESSITY Patent 1 Patent 2 Patent 3 Patent 4
*** *********

CRENESSITY - (50MG/1ML)

CRINECERFONT None
50MG/1ML
Less Than $1000 mn
None None
None None
None None
CRENESSITY is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
Yes
CRENESSITY Patent 1 Patent 2 Patent 3 Patent 4
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.